Abstract 4256: HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1)

结合 抗体 化学 药理学 抗体-药物偶联物 药品 癌症研究 医学 单克隆抗体 免疫学 数学 数学分析
作者
Wenjun Yan,You‐Zhi Zhang,Mengyun Zhang,Bo An,Yujing Zhang,Qing Xiong,Gui-Hai Chen,A. Fu,Dan Sun,Zhipeng Cai,Huaqin Chen,M Geng,Haibo Wang,Chengwei Yan,Yike Yuan,Tao Wei
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 4256-4256
标识
DOI:10.1158/1538-7445.am2025-4256
摘要

Abstract Introduction: Current ADC development focus on a small number of tumor-associated antigens (TAA). In recognizing heterogeneity of cancers and acquired resistance evolved in response to therapies, we have strategized our ADC development by focusing on discovering and develop novel TAAs. Methods: Integrative mining of large-scale omics databases was carried out to discover TAA. In-house antibody discovery and engineering platforms were employed for antibody discovery. In vitro assays were used to screen antibodies of high affinity, high specificity, efficient internalization and developability. A MMAE based ADC was evaluated in vitro for stability, cytotoxicity and bystander effect and in vivo in CDX models for anti-tumor efficacy. PK/TK and GLP toxicology studies were carried out in monkeys. Results: CDCP1 was identified to be significantly up-regulated in large proportions of cancer cells across many solid tumors, which was comparable to or higher expression than targets of the marketed ADC drugs. It is associated with cancer progression, metastasis and contributed to resistance to cancer therapies. We discovered and humanized a CDCP1-binding antibody (HY0001) which shows high affinity and specificity, and displays high efficiency of internalization and yet no agonist activity. We developed an ADC preclinical candidate (HY0001a) by conjugating HY0001 with vcMMAE at a DAR=4. HY0001a was rapidly internalized upon binding to CDCP1+ cancer cells and colocalized with lysosomes in 1∼2 hours after endocytosis. In vitro cytotoxicity assays with CDCP1+ cancer cell lines, HY0001a showed high cytotoxicity activities (IC50 = 0.05∼10 nM) in a target- and dose-dependent manner with strong bystander effect. HY0001a demonstrated strong anti-tumor efficacy in a target- and dose-dependent (1-5 mg/kg) manner when tested across multiple CDX models, including prostate, breast, pancreatic, colon, ovarian and bladder cancers. Like MMAE, HY0001a, but not HY0001, could arrest proliferative cancer cells in their G2M phase and significantly increase the number of apoptotic cells. HY0001a significant induced the apoptotic pathway in the tumor tissue of MDA-MB-231 CDX model. HY0001a is stable in biomatrix and possesses desired PK profiles (T1/2= 2-4 days in the CDX models and 2-3 days in cynomolgus monkeys). HY0001a showed toxicity profiles, similar to the marketed MMAE-based ADC drugs. We have completed development of the CMC processes and production of lots to enable the IND submission and early clinical trials. Conclusions: We identified CDCP1 as an excellent ADC TAA with great potential against multiple cancers. We discovered an antibody (HY0001) of high affinity, cancer cell-specific and efficiently internalization, and completed development of a preclinical candidate MMAE based ADC (HY0001a), which showed a great rationale for further clinical investigation to provide a novel cancer therapy. Citation Format: Wenjun Yan, Yang Zhang, Mengyun Zhang, Bo An, Yujing Zhang, Qing Xiong, Guifeng Chen, Ao Fu, Dan Sun, Xiaoqiang Cai, Huaqin Chen, Mingxia Geng, Haibo Wang, Chengwei Yan, Yike Yuan, Tao Wei. HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4256.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
天寒发布了新的文献求助10
刚刚
刚刚
骑蜗牛狂飙完成签到,获得积分10
1秒前
molihuakai的应助被阳光项链采纳,获得10
2秒前
2秒前
完美世界的应助被动人的巧蕊采纳,获得10
3秒前
简单夜山完成签到,获得积分10
3秒前
cenjin完成签到 ,获得积分10
3秒前
Steady完成签到 ,获得积分10
5秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
7秒前
我是老大的应助被川里九樱采纳,获得10
7秒前
7秒前
8秒前
SciGPT的应助被xiangnan采纳,获得10
8秒前
陷进发布了新的文献求助10
8秒前
彭于晏的应助被qqqqqqqqqq采纳,获得10
9秒前
9秒前
科研通AI6.3的应助被Wangyingjie5采纳,获得10
9秒前
123完成签到,获得积分10
9秒前
10秒前
范范完成签到 ,获得积分10
11秒前
11秒前
paxjustitia完成签到,获得积分10
12秒前
Fan发布了新的文献求助10
13秒前
17发布了新的文献求助10
13秒前
徐丽娜发布了新的文献求助10
13秒前
大橙子发布了新的文献求助10
13秒前
科目三的应助被1234nnnnnn采纳,获得10
14秒前
LL完成签到,获得积分10
14秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
15秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
15秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
15秒前
天天快乐的应助被时谨言采纳,获得10
15秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
16秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
16秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
16秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
16秒前
一一发布了新的文献求助10
16秒前
Elsevier大王的应助被zhikaiyici采纳,获得30
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194174
求助须知:如何正确求助?哪些是违规求助? 9580103
关于积分的说明 21869209
捐赠科研通 7793764
什么是DOI,文献DOI怎么找? 3437545
关于科研通互助平台的介绍 2560983
邀请新用户注册赠送积分活动 2484291